BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28385603)

  • 1. Research progress in advanced melanoma.
    Luo C; Shen J
    Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis in melanoma: an update with a focus on current targeted therapies.
    Jour G; Ivan D; Aung PP
    J Clin Pathol; 2016 Jun; 69(6):472-83. PubMed ID: 26865640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
    Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
    Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
    Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapies for melanoma brain metastases: which drug for whom and when?
    Ramanujam S; Schadendorf D; Long GV
    Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in esophageal cancer.
    Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D
    Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of first-line therapy in metastatic melanoma.
    Gibney GT; Atkins MB
    Cancer; 2019 Mar; 125(5):666-669. PubMed ID: 30695110
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

  • 14. The systemic treatment of advanced cutaneous melanoma.
    Logan TF
    Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
    [No Abstract]   [Full Text] [Related]  

  • 15. Melanoma vaccines: possible progress after years of frustration?
    Schmidt C
    J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
    [No Abstract]   [Full Text] [Related]  

  • 16. Discontinuation of melanoma combination immunotherapy.
    Baker H
    Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating metastatic melanoma in 2014: what just happened and what is next?
    Chapman PB
    Am Soc Clin Oncol Educ Book; 2014; ():16-9. PubMed ID: 24857055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
    Strickland LR; Pal HC; Elmets CA; Afaq F
    Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
    Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.